Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion

被引:0
|
作者
Thapa, R. [1 ]
Paudyal, G. [1 ]
机构
[1] Tilganga Inst Ophthalmol, Vitreoretinal Serv, POB 561, Kathmandu, Nepal
关键词
bevacizumab; branch retinal vein occlusion; central retinal vein occlusion; macular edema;
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction: Macular edema (ME) is the leading cause of visual impairment in retinal vein occlusion (RVO). Objective: To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin; Genentech) on ME secondary to RVO. Materials and methods: A prospective, interventional study was conducted among patients with ME due to RVO from June 2008 to February 2010. Intravitreal bevacizumab (1.25 mg/0.05 ml) was given at 4 to 6 weekly intervals until the ME subsided. Complete ophthalmic evaluation and measurement of central retinal thickness (CRT) by optical coherence tomography (OCT) were performed at baseline and follow up visits. Results: Thirty four eyes (18 CRVO and 16 BRVO) were included in the study. The mean duration of visual symptoms and follow up period were 5.1 months (range 0.3 - 24 months) and 7.5 +/- 4.8 months respectively. In CRVO, the CRT improved from 652 +/- 206 mu m at the baseline to 257 +/- 132 mu m (p < 0.0001) at the final follow up, and in BRVO, the CRT improved from 540 +/- 197 mu m to 219 +/- 135 mu m (p < 0.0001). The improvement in BCVA was significant at each follow up interval for BRVO; in CRVO, there was only a significant improvement between the baseline and the 6 weeks' follow up. BCVA was improved in 75 % cases of BRVO and in 61.6 % in CRVO at the final follow up. There were no ocular or systemic adverse effects. Conclusion: Intravitreal bevacizumab is an effective and safe drug for reducing ME and improving visual acuity secondary to RVO in the short term follow up.
引用
收藏
页码:63 / 68
页数:6
相关论文
共 50 条
  • [1] Treatment Results of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
    Choi, Yu-Jin
    Choi, Young Je
    Cho, Yong Wun
    Yoo, Woong-Sun
    Chung, In Young
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2021, 62 (09): : 1207 - 1217
  • [2] Bevacizumab for treatment of macular edema secondary to retinal vein occlusion
    Jaissle, G. B.
    Ziemssen, F.
    Petermeier, K.
    Szurman, P.
    Ladewig, M.
    Gelisken, F.
    Voelker, M.
    Holz, F. G.
    Bartz-Schmidt, K. U.
    OPHTHALMOLOGE, 2006, 103 (06): : 471 - 475
  • [3] Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Schaal, K. B.
    Hoeh, A. E.
    Scheuerle, A.
    Schuett, F.
    Dithmar, S.
    OPHTHALMOLOGE, 2007, 104 (04): : 285 - 289
  • [4] Changes in retinal layer morphology following intra-vitreal Ozurdex therapy for macular oedema secondary to Retinal Vein Occlusion
    Akshikar, Rashmi
    Sivaprasad, Sobha
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [5] Short Term Effect of Bevacizumab on Macular Edema in Central Retinal Vein Occlusion
    Attaran, M. S.
    Wiechens, B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [6] Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusion
    Parajuli, Anil
    Joshi, Purushottam
    Subedi, Prabha
    Pradhan, Chandni
    NEPALESE JOURNAL OF OPHTHALMOLOGY, 2020, 12 (02) : 281 - 289
  • [7] Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
    Mesa Gutierrez, Juan Carlos
    Arias Barquet, Luis
    Caminal Mitjana, Josep Maria
    Prades Almolda, Sergi
    Planas Domenech, N-Ria
    Pujol Goita, Octavi
    Rubio Caso, Marc
    Arruga Ginebreda, Jorge
    CLINICAL OPHTHALMOLOGY, 2008, 2 (04): : 787 - 791
  • [8] Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Yuan, Alex
    Ahmad, Baseer U.
    Xu, David
    Singh, Rishi P.
    Kaiser, Peter K.
    Martin, Daniel F.
    Sears, Jonathan E.
    Schachat, Andrew P.
    Ehlers, Justis P.
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2014, 7 (01) : 86 - 91
  • [9] Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Alex Yuan
    Baseer U.Ahmad
    David Xu
    Rishi P.Singh
    Peter K.Kaiser
    Daniel F.Martin
    Jonathan E.Sears
    Andrew P.Schachat
    Justis P.Ehlers
    International Journal of Ophthalmology, 2014, 7 (01) : 86 - 91
  • [10] Intravttreal bevacizumab (avastin) in the treatment of macular edema secondary to branch retinal vein occlusion
    Rabena, Melvin D.
    Pieramici, Dante J.
    Castellarin, Alessandro A.
    Nasir, Ma'an A.
    Avery, Robert L.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (04): : 419 - 425